Citius Oncology reports sustained quality-of-life gains in Lymphir trial responders
CTOR•Citius Oncology reported sustained skin-related quality-of-life improvements among patients responding to LYMPHIR in Study 302 for relapsed or refractory cutaneous T-cell lymphoma. The exploratory findings were presented at an annual meeting in Berlin on Oct. 8-10, 2026; the trial was not designed to evaluate these outcomes and no formal statistical comparisons were performed.
1. Quality-of-life findings
Citius Oncology reported that patients responding to LYMPHIR in pivotal Study 302 experienced sustained skin-related quality-of-life improvements. At treatment completion, responders reported better overall quality of life, and nearly a third of heavily pretreated patients with significant itch experienced sustained relief.
2. Exploratory outcomes
The findings were presented at the EORTC-CLTG annual meeting in Berlin, held Oct. 8-10, 2026. The quality-of-life outcomes were exploratory, the trial was not designed to evaluate them, and no formal statistical comparisons were performed; the results are not included in LYMPHIR's prescribing information.
